舍曲林合并利培酮治疗躯体形式障碍的对照研究  

Comparison study of Setraline and Setraline combined with Risperidone in treatment of somatoform disorders

作　　者：孔令军[1] 肖瑞林[1] 小云[1] 曾志金[1] 

机构地区：[1]江西省吉安市第三人民医院,江西吉安343000

出　　处：《中国民康医学》2009年第12期1365-1366,共2页Medical Journal of Chinese People’s Health

摘　　要：目的：探讨舍曲林联合利培酮治疗躯体形式障碍（SD）的效果及安全性。方法：将98例躯体形式障碍患者随机分为两组,研究组予以舍曲林合并利培酮治疗,对照组单用舍曲林治疗,疗程均为8周。在治疗前与治疗后第1、2、4、8周末,采用汉密顿抑郁量表（HAMD-17）、汉密顿焦虑量表（HAMA）和副反应量表（TESS）评定临床疗效及安全性。结果：治疗第2、4、8周末,两组HAMD、HAMA总评分差异有统计学意义（P〈0.05或P〈0.01）;第8周末研究组有效率90%,对照组72.9%,两组差异有统计学意义（P〈0.05）。两组不良反应表现均较轻。结论：舍曲林联合利培酮治疗躯体形式障碍较单用舍曲林疗效好,起效快,且不增加不良反应。Objective： To study the efficacy and safety of Setraline combined with Risperidone in the treatment of somatoform disorders. Methods：98 patients were assigned to Setraline （control group, n = 48） and Setraline combined with risperidone（study group, n = 50）, and treated for 8 weeks. Before t rear ment and at t he ends of the week 1,2,4,8, the clinical effects and side effects were assessed with HA M A, HA M D, TESS. Results： The scores of HA M A, HA M D in patients of the study group and control groups were significantly difference at week 2,4,8 （ P 〈 0.05 or P 〈 0. O1 ）. At the end of 8th week, effective rates of the study group and control group were respectively 88% and 75%, which had a significant difference（ P 〈 0.05）. Side effects of both the two group were milder. Condusion： Setraline combined with risperidone in treatment of somatoform disorders takes effect sbetter and faster than single Setraline and doesn＇t increase side effects.

关 键 词：舍曲林 利培酮 躯体形式障碍 不良反应 

分 类 号：R749.69[医药卫生—神经病学与精神病学]